Evaluation/NN
of/IN
Digital/JJ
PCR/NN
as/IN
a/DT
Technique/JJ
for/IN
Monitoring/JJ
Acute/JJ
Rejection/NN
in/IN
Kidney/NN
Transplantation/NN
./.
====================
Early/JJ
detection/NN
and/CC
proper/JJ
management/NN
of/IN
kidney/NN
rejection/NN
are/VBP
crucial/JJ
for/IN
the/DT
long-term/JJ
health/NN
of/IN
a/DT
transplant/JJ
recipient/JJ
./.
====================
Recipients/NNS
are/VBP
normally/RB
monitored/VBD
by/IN
serum/NN
creatinine/VBP
measurement/NN
and/CC
sometimes/RB
with/IN
graft/NN
biopsies/NNS
./.
====================
Donor-derived/JJ
cell-free/JJ
deoxyribonucleic/JJ
acid/NN
(/(
cfDNA/JJ
)/)
in/IN
the/DT
recipient/JJ
's/POS
plasma/NN
and/or/CC
urine/NN
may/MD
be/VB
a/DT
better/RBR
indicator/NN
of/IN
acute/JJ
rejection/NN
./.
====================
We/PRP
evaluated/VBD
digital/JJ
PCR/NN
(/(
dPCR/NN
)/)
as/IN
a/DT
system/NN
for/IN
monitoring/VBG
graft/NN
status/NN
using/VBG
single/JJ
nucleotide/NN
polymorphism/NN
(/(
SNP/NN
)/)
-based/JJ
detection/NN
of/IN
donor/NN
DNA/NN
in/IN
plasma/NN
or/CC
urine/NN
./.
====================
We/PRP
compared/VBD
the/DT
detection/NN
abilities/NNS
of/IN
the/DT
QX200/CD
,/,
RainDrop/NN
,/,
and/CC
QuantStudio/NN
3D/NN
dPCR/NN
systems/NNS
./.
====================
The/DT
QX200/CD
was/VBD
the/DT
most/JJS
accurate/JJ
and/CC
sensitive/JJ
./.
====================
Plasma/NN
and/or/CC
urine/NN
samples/NNS
were/VBD
isolated/VBN
from/IN
34/CD
kidney/NN
recipients/NNS
at/IN
multiple/JJ
time/NN
points/NNS
after/IN
transplantation/NN
,/,
and/CC
analyzed/VBD
by/IN
dPCR/NN
using/VBG
the/DT
QX200/CD
./.
====================
We/PRP
found/VBD
that/IN
donor/NN
DNA/NN
was/VBD
almost/RB
undetectable/JJ
in/IN
plasma/NN
DNA/NN
samples/NNS
,/,
whereas/IN
a/DT
high/JJ
percentage/NN
of/IN
donor/NN
DNA/NN
was/VBD
measured/VBN
in/IN
urine/NN
DNA/NN
samples/NNS
,/,
indicating/VBG
that/IN
urine/NN
is/VBZ
a/DT
good/JJ
source/NN
of/IN
cfDNA/JJ
for/IN
patient/NN
monitoring/VBG
./.
====================
We/PRP
found/VBD
that/IN
at/IN
least/JJS
24/CD
%/NN
of/IN
the/DT
highly/RB
polymorphic/JJ
SNPs/NNS
used/VBN
to/TO
identify/VB
individuals/NNS
could/MD
also/RB
identify/VBP
donor/NN
cfDNA/JJ
in/IN
transplant/JJ
patient/NN
samples/NNS
./.
====================
Our/PRP$
results/NNS
further/RB
showed/VBD
that/IN
autosomal/JJ
,/,
sex-specific/JJ
,/,
and/CC
mitochondrial/JJ
SNPs/NNS
were/VBD
suitable/JJ
markers/NNS
for/IN
identifying/VBG
donor/NN
cfDNA/JJ
./.
====================
Finally/RB
,/,
we/PRP
found/VBD
that/IN
donor-derived/JJ
cfDNA/JJ
measurement/NN
by/IN
dPCR/NN
was/VBD
not/RB
sufficient/JJ
to/TO
predict/VB
a/DT
patient/NN
's/POS
clinical/JJ
condition/NN
./.
====================
Our/PRP$
results/NNS
indicate/VBP
that/IN
donor-derived/JJ
cfDNA/NN
is/VBZ
not/RB
an/DT
accurate/JJ
predictor/NN
of/IN
kidney/NN
status/NN
in/IN
kidney/NN
transplant/JJ
patients/NNS
./.
====================
Kidney/NN
transplantation/NN
is/VBZ
a/DT
necessity/NN
for/IN
patients/NNS
who/WP
have/VBP
non-recovery/RB
of/IN
kidney/NN
function/NN
./.
====================
Transplant/JJ
patients/NNS
usually/RB
have/VBP
a/DT
high/JJ
risk/NN
of/IN
complications/NNS
in/IN
the/DT
early/JJ
post-operative/JJ
period/NN
(/(
3–6/CD
months/NNS
)/)
[/(
1/CD
]/)
./.
====================
Diagnoses/NNS
of/IN
kidney/NN
dysfunction/NN
include/VBP
acute/JJ
rejection/NN
,/,
acute/JJ
tubular/JJ
necrosis/NN
,/,
glomerulonephritis/NN
,/,
calcineurin/NN
inhibitor/NN
toxicity/NN
,/,
and/CC
non-specific/JJ
injury/NN
./.
====================
Early/JJ
diagnosis/NN
and/CC
treatment/NN
are/VBP
very/RB
important/JJ
for/IN
a/DT
patient/NN
's/POS
long-term/JJ
health/NN
./.
====================
Biopsy/NN
and/CC
measurement/NN
of/IN
creatinine/NN
levels/NNS
are/VBP
standard/JJ
ways/NNS
to/TO
monitor/VB
patients/NNS
[/(
2/CD
]/)
./.
====================
The/DT
disadvantage/JJ
of/IN
using/VBG
biopsies/NNS
is/VBZ
that/DT
they/PRP
cause/VBP
injury/NN
to/TO
the/DT
kidney/NN
,/,
and/CC
can/MD
cause/VB
secondary/JJ
complications/NNS
./.
====================
The/DT
disadvantage/JJ
of/IN
measuring/VBG
creatinine/NN
levels/NNS
is/VBZ
that/DT
this/DT
is/VBZ
a/DT
low/JJ
specificity/NN
assay/NN
./.
====================
For/IN
these/DT
reasons/NNS
,/,
noninvasive/JJ
diagnostic/JJ
tools/NNS
that/DT
can/MD
outperform/VB
the/DT
current/JJ
standard/JJ
transplantation/NN
monitoring/VBG
system/NN
are/VBP
needed/VBN
./.
====================
It/PRP
has/VBZ
been/VBN
reported/VBN
that/IN
total/JJ
cell-free/JJ
deoxyribonucleic/JJ
acid/NN
(/(
cfDNA/JJ
)/)
or/CC
donor-derived/JJ
cfDNA/JJ
in/IN
plasma/NN
or/CC
urine/NN
can/MD
be/VB
used/VBN
as/IN
a/DT
potential/JJ
biomarker/NN
for/IN
the/DT
early/JJ
detection/NN
of/IN
kidney/NN
dysfunction/NN
after/IN
transplantation/NN
[/(
34567/CD
]/)
./.
====================
Several/JJ
different/JJ
cfDNA/NN
quantification/NN
techniques/NNS
have/VBP
been/VBN
investigated/VBN
for/IN
use/NN
in/IN
examining/VBG
cfDNA/NN
as/IN
biomarker/NN
of/IN
acute/JJ
rejection/NN
./.
====================
These/DT
techniques/NNS
include/VBP
quantitative/JJ
polymerase/NN
chain/NN
reaction/NN
(/(
PCR/NN
)/)
using/VBG
Y-chromosome/JJ
genes/NNS
[/(
1/CD
]/)
,/,
digital/JJ
PCR/NN
(/(
dPCR/NN
)/)
using/VBG
Y-chromosome/JJ
genes/NNS
[/(
89/CD
]/)
or/CC
single/JJ
nucleotide/NN
polymorphisms/NNS
(/(
SNPs/NNS
)/)
[/(
10/CD
]/)
,/,
and/CC
massive/JJ
parallel/NN
shotgun/JJ
sequencing/NN
using/VBG
SNPs/NNS
[/(
811/CD
]/)
./.
====================
Several/JJ
studies/NNS
reported/VBD
that/IN
dPCR/NN
was/VBD
especially/RB
cost-effective/JJ
,/,
rapid/JJ
,/,
and/CC
sensitive/JJ
for/IN
quantifying/VBG
circulating/VBG
donor/NN
DNA/NN
in/IN
plasma/NN
or/CC
urine/NN
samples/NNS
from/IN
transplant/JJ
patients/NNS
[/(
91012/CD
]/)
./.
====================
However/RB
,/,
it/PRP
is/VBZ
still/RB
not/RB
clear/JJ
whether/IN
dPCR/NN
can/MD
be/VB
used/VBN
in/IN
a/DT
clinic/JJ
to/TO
accurately/RB
monitor/NN
the/DT
conditions/NNS
of/IN
transplanted/VBN
organs/NNS
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
evaluated/VBD
dPCR-based/VBN
kidney/NN
transplant/JJ
recipient/JJ
monitoring/VBG
by/IN
measuring/VBG
the/DT
levels/NNS
of/IN
circulating/VBG
donor-derived/JJ
cfDNA/JJ
in/IN
patient/NN
plasma/NN
and/or/CC
urine/NN
./.
====================
Patients/NNS
====================
As/IN
a/DT
pilot/NN
test/NN
,/,
genomic/JJ
DNA/NN
and/CC
cfDNA/JJ
were/VBD
isolated/VBN
from/IN
three/CD
different/JJ
pairs/NNS
of/IN
donor/NN
and/CC
recipient/JJ
samples/NNS
(/(
blood/NN
,/,
plasma/NN
,/,
and/CC
urine/NN
)/)
collected/VBD
at/IN
Asan/NN
Medical/JJ
Center/NN
./.
====================
For/IN
clinical/JJ
sample/JJ
screening/VBG
using/VBG
SNP-based/JJ
dPCR/NN
,/,
the/DT
blood/NN
(/(
n/NN
=/JJ
72/CD
)/)
,/,
plasma/NN
(/(
n/NN
=/JJ
72/CD
)/)
,/,
and/CC
urine/NN
(/(
n/NN
=/JJ
69/CD
)/)
samples/NNS
were/VBD
collected/VBN
from/IN
a/DT
total/JJ
of/IN
34/CD
kidney/NN
transplant/JJ
recipients/NNS
with/IN
different/JJ
clinical/JJ
conditions/NNS
at/IN
Kyung/JJ
Hee/NNP
University/JJ
Hospital/JJ
at/IN
Gangdong/JJ
./.
====================
Patient/JJ
were/VBD
stable/JJ
,/,
or/CC
experiencing/VBG
acute/JJ
rejection/NN
,/,
acute/JJ
tubular/JJ
necrosis/NN
,/,
glomerulonephritis/NN
,/,
calcineurin-inhibitor/NN
toxicity/NN
,/,
or/CC
suffering/VBG
from/IN
non-specific/JJ
injury/NN
./.
====================
The/DT
study/NN
protocols/NNS
were/VBD
approved/VBN
by/IN
the/DT
Institutional/JJ
Review/NN
Board/JJ
of/IN
the/DT
Asan/NN
Medical/JJ
Center/NN
and/CC
Kyung/JJ
Hee/JJ
University/NN
Hospital/JJ
at/IN
Gangdong/JJ
./.
====================
Written/RB
informed/VBN
consent/NN
was/VBD
obtained/VBN
from/IN
all/DT
patients/NNS
./.
====================
Preparation/NN
of/IN
genomic/JJ
DNA/NN
and/CC
cfDNA/NN
for/IN
dPCR/NN
====================
Blood/NN
was/VBD
centrifuged/JJ
at/IN
1,800/CD
×g/NN
for/IN
10/CD
minutes/NNS
to/TO
separate/VB
the/DT
buffy/JJ
coat/NN
from/IN
the/DT
plasma/NN
./.
====================
The/DT
buffy/JJ
coat/NN
was/VBD
used/VBN
to/TO
isolate/VB
genomic/JJ
DNA/NN
using/VBG
a/DT
Qiagen/NN
DNA/NN
blood/NN
mini/NNS
kit/NN
(/(
Qiagen/NN
,/,
Hilden/JJ
,/,
Germany/NNP
)/)
./.
====================
According/VBG
to/TO
standard/JJ
protocols/NNS
,/,
genomic/JJ
DNA/NN
was/VBD
eluted/VBN
using/VBG
200/CD
µL/NN
of/IN
elution/NN
buffer/NN
./.
====================
Plasma/NN
(/(
1/CD
mL/NN
)/)
and/CC
urine/NN
(/(
3/CD
mL/NN
)/)
were/VBD
centrifuged/JJ
at/IN
11,000/CD
×g/JJ
for/IN
3/CD
min/NN
,/,
and/CC
1,800/CD
×g/JJ
for/IN
10/CD
min/NN
,/,
respectively/RB
,/,
to/TO
remove/VB
cells/NNS
./.
====================
cfDNA/JJ
was/VBD
isolated/VBN
from/IN
plasma/NN
and/CC
urine/NN
using/VBG
a/DT
Qiagen/NN
Circulating/VBG
Nucleic/JJ
Acid/NN
kit/NN
and/CC
eluted/VBN
using/VBG
50/CD
µL/NN
of/IN
elution/NN
buffer/NN
./.
====================
DNA/NN
was/VBD
stored/VBN
at/IN
−20℃/CD
./.
====================
Selection/NN
of/IN
donor-specific/JJ
SNP/NN
markers/NNS
====================
In/IN
order/NN
to/TO
differentiate/VB
donor/NN
DNA/NN
from/IN
recipient/JJ
DNA/NN
,/,
SNP/NN
markers/NNS
were/VBD
selected/VBN
from/IN
a/DT
panel/NN
of/IN
SNPs/NNS
used/VBN
for/IN
sex/NN
determination/NN
or/CC
identification/NN
of/IN
individuals/NNS
[/(
13/CD
]/)
./.
====================
A/DT
total/JJ
of/IN
seven/CD
highly/RB
polymorphic/JJ
mitochondrial/JJ
DNA/NN
(/(
mtDNA/JJ
)/)
SNPs/NNS
were/VBD
also/RB
selected/VBN
from/IN
mtDB/NN
(/(
http/NN
:/:
//www.mtdb.igp.uu.se//JJ
)/)
and/CC
in-house/IN
Korean/JJ
mtDNA/JJ
variant/JJ
data/NNS
,/,
and/CC
were/VBD
used/VBN
to/TO
detect/VB
donor-specific/JJ
mtDNA/JJ
in/IN
patient/NN
samples/NNS
./.
====================
We/PRP
designed/VBD
several/JJ
TaqMan/NN
probe/NN
sets/NNS
to/TO
detect/VB
each/DT
of/IN
two/CD
alleles/NNS
in/IN
our/PRP$
dPCR/NN
screen/NN
using/VBG
the/DT
fluorescent/JJ
dyes/NNS
FAM/NN
and/CC
VIC/NN
(/(
Thermo/DT
Fisher/RB
Scientific/JJ
,/,
Waltham/NNP
,/,
MA/NN
,/,
USA/NNP
)/)
./.
====================
dPCR/NN
experiments/NNS
====================
Initially/RB
,/,
three/CD
different/JJ
dPCR/NN
systems/NNS
(/(
QX200/CD
,/,
Bio-Rad/NNP
,/,
Hercules/NNS
,/,
CA/NNP
,/,
USA/NNP
;/:
RainDrop/NNP
,/,
RainDance/NN
Technologies/NNS
,/,
Billrica/NNP
,/,
MA/NN
,/,
USA/NNP
;/:
QuantStudio/NNP
3D/NN
,/,
Life/NNP
Technologies/NNS
,/,
Carlsbad/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
were/VBD
tested/VBN
to/TO
compare/VB
their/PRP$
sensitivity/NN
and/CC
accuracy/RB
using/VBG
SNP/NN
rs543840/RB
(/(
A/G/NN
)/)
with/IN
10/CD
ng/NN
of/IN
control/JJ
genomic/JJ
DNA/NN
having/VBG
one/CD
of/IN
three/CD
known/VBN
genotypes/NNS
(/(
AA/NNP
,/,
AG/NN
,/,
or/CC
GG/NNS
)/)
./.
====================
For/IN
the/DT
quantification/NN
of/IN
cfDNA/JJ
in/IN
transplant/JJ
patient/NN
plasma/NN
and/CC
urine/NN
,/,
the/DT
Bio-Rad/JJ
QX200/CD
dPCR/NN
system/NN
was/VBD
used/VBN
with/IN
3.5/CD
µL/NN
of/IN
isolated/VBN
sample/NN
cfDNA/JJ
./.
====================
All/DT
reactions/NNS
were/VBD
prepared/VBN
using/VBG
the/DT
manufacturer/NN
's/POS
standard/JJ
protocol/NN
(/(
Bio-Rad/NNP
)/)
./.
====================
Each/DT
reaction/NN
contained/VBD
10/CD
µL/NN
of/IN
2×/JJ
ddPCR/NN
Supermix/JJ
for/IN
Probes/NNS
(/(
Bio-Rad/NNP
)/)
,/,
1/CD
µL/NN
of/IN
40×/CD
TaqMan/NN
Probe/NN
(/(
Thermo/DT
Fisher/RB
Scientific/JJ
)/)
,/,
3.5/CD
or/CC
5/CD
µL/NN
of/IN
cfDNA/JJ
(/(
1:20/CD
diluted/VBN
cfDNA/JJ
in/IN
the/DT
case/NN
of/IN
mtDNA/JJ
detection/NN
)/)
as/IN
template/JJ
,/,
and/CC
the/DT
distilled/JJ
water/NN
necessary/JJ
to/TO
reach/VB
a/DT
total/JJ
reaction/NN
volume/NN
of/IN
20/CD
µL/NN
./.
====================
Droplets/NNS
were/VBD
generated/VBN
using/VBG
the/DT
QX200/CD
droplet/NN
generator/NN
(/(
Bio-Rad/NNP
)/)
according/VBG
to/TO
the/DT
manufacturer/NN
's/POS
protocols/NNS
./.
====================
The/DT
PCR/NN
cycling/NN
conditions/NNS
were/VBD
95℃/CD
for/IN
10/CD
min/NN
,/,
followed/VBN
by/IN
40/CD
cycles/NNS
of/IN
94℃/CD
for/IN
30/CD
s/NNS
and/CC
60℃/CD
for/IN
60/CD
s/NNS
,/,
with/IN
a/DT
final/JJ
10-min/NN
incubation/NN
at/IN
98℃/CD
./.
====================
Droplets/NNS
were/VBD
read/VBN
in/IN
the/DT
QX200/CD
droplet/NN
reader/NN
,/,
and/CC
analyzed/VBD
using/VBG
the/DT
QuantaSoft/JJ
software/JJ
,/,
version/NN
1.6.6/CD
(/(
Bio-Rad/NNP
)/)
./.
====================
We/PRP
measured/VBD
the/DT
positive/JJ
counts/NNS
of/IN
each/DT
allele/NN
directly/RB
,/,
or/CC
the/DT
calculated/JJ
counts/NNS
of/IN
each/DT
allele/NN
based/VBN
on/IN
a/DT
Poisson/NN
distribution/NN
./.
====================
These/DT
values/NNS
were/VBD
then/RB
used/VBN
to/TO
express/VB
the/DT
minor/JJ
allele/NN
(/(
donor/NN
DNA/NN
)/)
counts/NNS
as/IN
a/DT
percentage/NN
of/IN
the/DT
total/JJ
DNA/NN
counts/NNS
./.
====================
In/IN
case/NN
of/IN
homozygous/JJ
donors/NNS
(/(
two/CD
A/DT
alleles/NNS
)/)
and/CC
recipients/NNS
(/(
two/CD
B/NN
alleles/NNS
)/)
,/,
the/DT
donor/NN
DNA/NN
counts/NNS
and/CC
percentages/VBZ
were/VBD
easy/RB
to/TO
calculate/JJ
because/IN
the/DT
donor/NN
DNA/NN
counts/NNS
were/VBD
simply/RB
the/DT
positive/JJ
counts/NNS
of/IN
the/DT
A/NN
allele/NN
./.
====================
However/RB
,/,
in/IN
case/NN
of/IN
heterozygous/JJ
donors/NNS
(/(
A/DT
and/CC
B/NN
alleles/NNS
)/)
and/CC
homozygous/JJ
recipients/NNS
(/(
two/CD
B/NN
alleles/NNS
)/)
,/,
the/DT
corrected/JJ
donor/NN
DNA/NN
counts/NNS
were/VBD
calculated/VBN
by/IN
doubling/JJ
the/DT
total/JJ
positive/JJ
counts/NNS
of/IN
the/DT
A/NN
allele/NN
,/,
whereas/IN
the/DT
corrected/JJ
recipient/JJ
DNA/NN
counts/NNS
were/VBD
calculated/VBN
by/IN
subtracting/VBG
the/DT
total/JJ
positive/JJ
counts/NNS
of/IN
the/DT
A/NN
allele/NN
from/IN
the/DT
total/JJ
positive/JJ
counts/NNS
of/IN
the/DT
B/NN
allele/NN
./.
====================
Finally/RB
,/,
the/DT
donor/NN
DNA/NN
percentage/NN
was/VBD
calculated/VBN
as/IN
the/DT
corrected/JJ
donor/NN
DNA/NN
counts/NNS
divided/VBN
by/IN
the/DT
total/JJ
positive/JJ
DNA/NN
counts/NNS
,/,
multiplied/JJ
by/IN
100/CD
./.
====================
Statistical/JJ
analysis/NN
====================
Statistical/JJ
analyses/NNS
were/VBD
performed/VBN
using/VBG
SPSS/NN
version/NN
18/CD
(/(
SPSS/NN
Inc./NNP
,/,
Chicago/JJ
,/,
IL/NN
,/,
USA/NN
)/)
./.
====================
The/DT
level/NN
of/IN
statistical/JJ
significance/NN
(/(
p/NN
)/)
was/VBD
calculated/VBN
with/IN
a/DT
student/JJ
's/POS
t/NN
test/NN
or/CC
ANOVA/NN
test/NN
to/TO
compare/VB
clinical/JJ
subgroups/NNS
of/IN
transplant/JJ
patients/NNS
,/,
such/JJ
as/IN
stable/JJ
and/CC
acute/JJ
rejection/NN
./.
====================
Pearson/NN
's/POS
correlation/NN
coefficients/NNS
(/(
r/NN
)/)
were/VBD
also/RB
calculated/VBN
to/TO
compare/VB
SNP/NN
marker/NN
types/NNS
to/TO
detect/VB
donor/NN
cfDNA/JJ
./.
====================
Linkage/JJ
between/IN
highly/RB
polymorphic/JJ
mitochondrial/JJ
SNP/NN
markers/NNS
were/VBD
examined/VBN
with/IN
the/DT
square/NN
of/IN
correlation/NN
coefficients/NNS
(/(
r2/NN
)/)
using/VBG
HapAnalyzer/NN
program/NN
[/(
14/CD
]/)
./.
====================
Evaluation/NN
of/IN
SNP/NN
detection/NN
in/IN
genomic/JJ
DNA/NN
by/IN
three/CD
dPCR/NN
instruments/NNS
====================
Prior/JJ
to/TO
using/VBG
dPCR/NN
to/TO
detect/VB
donor/NN
DNA/NN
in/IN
transplant/JJ
patient/NN
cfDNA/JJ
samples/NNS
,/,
we/PRP
tested/VBD
the/DT
performance/NN
of/IN
three/CD
different/JJ
dPCR/NN
instruments/NNS
(/(
Bio-Rad/NNP
QX200/CD
,/,
RainDance/NN
RainDrop/NN
,/,
and/CC
Life/JJ
Technologies/NNS
QuantStudio/NNP
3D/NN
)/)
using/VBG
control/JJ
genomic/JJ
DNA/NN
samples/NNS
with/IN
three/CD
different/JJ
genotypes/NNS
of/IN
a/DT
SNP/NN
(/(
rs543840/CD
)/)
(/(
sample/JJ
1/CD
,/,
AA/NNP
;/:
sample/RB
2/CD
,/,
AG/NN
;/:
sample/RB
3/CD
,/,
GG/NNS
)/)
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
The/DT
Bio-Rad/JJ
QX200/CD
system/NN
had/VBD
the/DT
highest/JJS
counts/NNS
and/CC
best/JJS
genotype/NN
clustering/NN
in/IN
all/DT
samples/NNS
./.
====================
The/DT
RainDrop/NN
system/NN
had/VBD
a/DT
high/JJ
false-positive/JJ
rate/NN
in/IN
the/DT
homozygous/JJ
samples/NNS
(/(
sample/JJ
1/CD
,/,
1.19/CD
%/NN
;/:
sample/JJ
3/CD
,/,
17.75/CD
%/NN
)/)
,/,
and/CC
an/DT
unequal/JJ
allelic/JJ
ratio/NN
(/(
A/DT
:/:
G/NN
=/JJ
1:3/CD
)/)
in/IN
the/DT
heterozygous/JJ
sample/JJ
(/(
sample/JJ
2/CD
)/)
./.
====================
The/DT
QuantStudio/JJ
3D/NN
system/NN
gave/VBD
clear/JJ
clustering/NN
in/IN
the/DT
heterozygous/JJ
sample/JJ
(/(
sample/NN
2/CD
)/)
but/CC
gave/VBD
weak/JJ
clustering/NN
(/(
sample/NN
1/CD
)/)
and/CC
high/JJ
false/VBP
positive/JJ
counts/NNS
(/(
sample/NN
3/CD
)/)
in/IN
the/DT
homozygous/JJ
samples/NNS
./.
====================
Therefore/RB
,/,
among/IN
the/DT
three/CD
dPCR/NN
systems/NNS
tested/VBN
in/IN
this/DT
study/NN
,/,
the/DT
Bio-Rad/JJ
QX200/CD
system/NN
had/VBD
the/DT
best/JJS
performance/NN
in/IN
detecting/VBG
SNPs/NNS
in/IN
control/JJ
genomic/JJ
DNA/NN
samples/NNS
./.
====================
The/DT
Bio-Rad/JJ
QX200/CD
dPCR/NN
system/NN
was/VBD
thus/RB
chosen/NN
for/IN
dPCR/NN
screening/NN
of/IN
transplant/JJ
patient/NN
cfDNA/NN
samples/NNS
./.
====================
Selection/NN
of/IN
highly/RB
polymorphic/JJ
autosomal/JJ
and/CC
mitochondrial/JJ
SNPs/NNS
as/IN
donor-specific/JJ
DNA/NN
markers/NNS
====================
Several/JJ
studies/NNS
have/VBP
used/VBN
genetic/JJ
signature/NN
detection/NN
of/IN
transplanted/VBN
organs/NNS
based/VBN
on/IN
SNPs/NNS
[/(
8101516/CD
]/)
./.
====================
However/RB
,/,
it/PRP
is/VBZ
still/RB
not/RB
clear/JJ
how/WRB
many/JJ
SNPs/NNS
should/MD
be/VB
genotyped/VBN
for/IN
accurate/JJ
detection/NN
of/IN
donor-specific/JJ
DNA/NN
in/IN
transplant/JJ
patients/NNS
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
tested/VBD
the/DT
ability/NN
of/IN
27/CD
highly/RB
polymorphic/JJ
SNPs/NNS
used/VBN
for/IN
human/JJ
identification/NN
to/TO
distinguish/VB
donor-specific/JJ
DNA/NN
from/IN
paired/JJ
transplant/JJ
patient/NN
DNA/NN
./.
====================
To/TO
determine/VB
the/DT
appropriate/JJ
number/NN
of/IN
SNPs/NNS
for/IN
donor-specific/JJ
DNA/NN
detection/NN
,/,
we/PRP
screened/VBD
the/DT
genotypes/NNS
of/IN
the/DT
27/CD
SNPs/NNS
,/,
and/CC
the/DT
genotypes/NNS
of/IN
two/CD
additional/JJ
sex-specific/JJ
SNPs/NNS
used/VBN
for/IN
sex/NN
determination/NN
(/(
AMEL-1/NN
&/CC
ZF-1/NN
)/)
./.
====================
The/DT
genomic/JJ
DNA/NN
of/IN
three/CD
kidney/NN
donor/NN
and/CC
recipient/JJ
pairs/NNS
was/VBD
analyzed/VBN
by/IN
capillary/JJ
sequencing/NN
(/(
Table/JJ
1/CD
)/)
./.
====================
In/IN
the/DT
case/NN
of/IN
a/DT
transplant/JJ
between/IN
unrelated/JJ
individuals/NNS
(/(
patient/NN
1/CD
,/,
wife/IN
to/TO
husband/CC
)/)
,/,
among/IN
27/CD
markers/NNS
,/,
11/CD
donor-specific/JJ
SNPs/NNS
(/(
five/CD
homozygous/JJ
and/CC
six/CD
heterozygous/JJ
alleles/NNS
;/:
40.7/CD
%/NN
)/)
were/VBD
identified/VBN
./.
====================
However/RB
,/,
in/IN
case/NN
of/IN
transplants/NNS
between/IN
related/JJ
individuals/NNS
(/(
patient/NN
2/CD
and/CC
patient/NN
3/CD
,/,
both/CC
cases/NNS
are/VBP
transplants/NNS
from/IN
mother/NN
to/TO
daughter/NN
)/)
,/,
seven/CD
and/CC
six/CD
heterozygous/JJ
SNPs/NNS
(/(
25.9/CD
%/NN
and/CC
22.2/CD
%/NN
of/IN
alleles/NNS
tested/VBN
)/)
were/VBD
detected/VBN
as/IN
donor-specific/JJ
markers/NNS
,/,
respectively/RB
(/(
Table/JJ
1/CD
)/)
./.
====================
These/DT
data/NNS
indicate/VBP
that/IN
using/VBG
approximately/RB
24/CD
%/NN
of/IN
the/DT
highly/RB
polymorphic/JJ
SNPs/NNS
used/VBN
to/TO
identify/VB
individuals/NNS
would/MD
be/VB
sufficient/JJ
to/TO
detect/VB
donor-specific/JJ
DNA/NN
in/IN
transplant/JJ
monitoring/VBG
,/,
even/RB
in/IN
transplants/NNS
between/IN
related/JJ
individuals/NNS
./.
====================
The/DT
detection/NN
of/IN
nuclear/JJ
DNA/NN
is/VBZ
not/RB
easy/RB
due/JJ
to/TO
limited/JJ
amounts/NNS
of/IN
donor/NN
DNA/NN
in/IN
plasma/NN
or/CC
urine/NN
cfDNA/JJ
samples/NNS
./.
====================
However/RB
,/,
high/JJ
copy/NN
numbers/NNS
of/IN
the/DT
mitochondrial/JJ
genome/NN
are/VBP
usually/RB
present/JJ
in/IN
cfDNA/JJ
samples/NNS
./.
====================
In/IN
order/NN
to/TO
identify/VB
candidate/NN
mtDNA/JJ
variants/NNS
as/IN
donor-specific/JJ
DNA/NN
markers/NNS
,/,
we/PRP
selected/VBD
19/CD
highly/RB
polymorphic/JJ
mitochondrial/JJ
SNPs/NNS
with/IN
high/JJ
minor/JJ
allele/NN
frequency/NN
(/(
MAF/NN
>/JJR
0.20/CD
)/)
at/IN
mtDB/NN
(/(
http/NN
:/:
//www.mtdb.igp.uu.se//JJ
)/)
and/CC
one/CD
in-house/RB
mtDNA/JJ
variant/JJ
data/NNS
with/IN
MAF/NN
>/JJR
0.30/CD
(/(
n/NN
=/JJ
24/CD
Korean/JJ
DNA/NN
samples/NNS
)/)
./.
====================
For/IN
the/DT
detection/NN
of/IN
donor-specific/JJ
DNA/NN
in/IN
plasma/NN
or/CC
urine/NN
cfDNA/JJ
samples/NNS
after/IN
transplantation/NN
,/,
a/DT
total/JJ
of/IN
seven/CD
highly/RB
polymorphic/JJ
mitochondrial/JJ
SNPs/NNS
were/VBD
finally/RB
selected/VBN
based/VBN
on/IN
having/VBG
high/JJ
MAFs/NNS
(/(
>/JJR
0.2/CD
)/)
in/IN
additional/JJ
Korean/JJ
DNA/NN
samples/NNS
(/(
n/NN
=/JJ
38/CD
)/)
,/,
and/CC
following/VBG
exclusion/NN
of/IN
three/CD
tightly/RB
linked/VBN
variants/NNS
(/(
linkage/NN
with/IN
r2/NN
=/JJ
1/CD
)/)
(/(
Table/JJ
2/CD
)/)
./.
====================
Detection/NN
of/IN
donor-specific/JJ
DNA/NN
in/IN
kidney/NN
recipients/NNS
'/``
plasma/NN
and/CC
urine/NN
cfDNA/NN
samples/NNS
using/VBG
dPCR/NN
====================
For/IN
the/DT
detection/NN
of/IN
donor-specific/JJ
DNA/NN
variants/NNS
in/IN
cfDNA/JJ
samples/NNS
from/IN
transplant/JJ
patients/NNS
,/,
we/PRP
finally/RB
selected/VBN
36/CD
candidate/NN
SNPs/NNS
from/IN
three/CD
different/JJ
DNA/NN
sources/NNS
:/:
two/CD
SNPs/NNS
commonly/RB
used/VBN
for/IN
sex-determination/JJ
,/,
27/CD
autosomal/JJ
SNPs/NNS
commonly/RB
used/VBN
for/IN
human/JJ
identification/NN
,/,
and/CC
seven/CD
highly/RB
polymorphic/JJ
mitochondrial/JJ
SNPs/NNS
./.
====================
As/IN
a/DT
pilot/NN
test/NN
,/,
we/PRP
performed/VBD
dPCR/NN
screening/NN
with/IN
one/CD
SNP/NN
from/IN
each/DT
category/NN
,/,
and/CC
examined/VBD
plasma/NN
and/CC
urine/NN
cfDNA/JJ
samples/NNS
from/IN
a/DT
kidney/NN
transplant/JJ
recipient/JJ
with/IN
acute/JJ
tubular/JJ
necrosis/NN
at/IN
day/NN
18/CD
after/IN
transplantation/NN
./.
====================
Using/VBG
any/DT
of/IN
the/DT
three/CD
SNPs/NNS
,/,
we/PRP
were/VBD
able/JJ
to/TO
detect/VB
circulating/VBG
donor/NN
DNA/NN
in/IN
urine/NN
cfDNA/JJ
samples/NNS
,/,
but/CC
not/RB
in/IN
plasma/NN
cfDNA/NN
samples/NNS
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
As/IN
shown/VBN
in/IN
Fig/NN
./.
====================
2/CD
,/,
limited/JJ
amounts/NNS
of/IN
donor-specific/JJ
DNA/NN
(/(
0/CD
%/NN
–0.25/CD
%/NN
of/IN
total/JJ
DNA/NN
)/)
were/VBD
detected/VBN
in/IN
plasma/NN
cfDNA/NN
samples/NNS
,/,
whereas/IN
high/JJ
amounts/NNS
of/IN
donor-specific/JJ
DNA/NN
(/(
56/CD
%/NN
–74/CD
%/NN
of/IN
total/JJ
DNA/NN
)/)
were/VBD
detected/VBN
in/IN
urine/NN
cfDNA/JJ
samples/NNS
using/VBG
all/DT
three/CD
SNP/NN
markers/NNS
./.
====================
Thus/RB
,/,
our/PRP$
results/NNS
indicate/VBP
that/IN
plasma/NN
cfDNA/NN
is/VBZ
not/RB
appropriate/JJ
for/IN
kidney/NN
transplant/JJ
monitoring/VBG
,/,
but/CC
urine/NN
is/VBZ
a/DT
very/RB
good/JJ
source/NN
of/IN
cfDNA/JJ
for/IN
monitoring/VBG
kidney/NN
transplant/JJ
patients/NNS
./.
====================
Furthermore/RB
,/,
using/VBG
the/DT
sex-specific/JJ
and/CC
autosomal/JJ
SNPs/NNS
led/VBD
to/TO
identification/NN
of/IN
a/DT
very/RB
similar/JJ
percentage/NN
of/IN
donor-specific/JJ
DNA/NN
(/(
57/CD
%/NN
vs./CC
56/CD
%/NN
)/)
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
a/DT
higher/JJR
percentage/NN
of/IN
donor-specific/JJ
DNA/NN
(/(
74/CD
%/NN
)/)
was/VBD
detected/VBN
using/VBG
the/DT
mtDNA/JJ
SNP/NN
as/IN
a/DT
marker/NN
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
We/PRP
also/RB
observed/VBN
a/DT
strong/JJ
correlation/NN
between/IN
the/DT
mtDNA/JJ
and/CC
nuclear/JJ
DNA/NN
SNPs/NNS
(/(
Pearson/NN
's/POS
correlation/NN
coefficient/JJ
r/NN
=/JJ
0.57–0.83/CD
)/)
as/IN
well/RB
as/IN
between/IN
sex-specific/JJ
and/CC
autosomal/JJ
SNPs/NNS
(/(
r/NN
=/JJ
0.90/CD
,/,
p/NN
=/JJ
0.0007/CD
)/)
in/IN
a/DT
comparison/NN
of/IN
multiple/JJ
sample/JJ
tests/NNS
(/(
Fig/NN
./.
====================
3/CD
)/)
./.
====================
These/DT
results/NNS
indicate/VBP
that/IN
dPCR/NN
can/MD
be/VB
useful/JJ
for/IN
SNP-based/JJ
detection/NN
of/IN
donor/NN
DNA/NN
in/IN
the/DT
urine/NN
of/IN
kidney/NN
recipients/NNS
following/VBG
transplantation/NN
./.
====================
Evaluation/NN
of/IN
dPCR/NN
screening/NN
of/IN
clinical/JJ
samples/NNS
from/IN
kidney/NN
transplant/JJ
recipients/NNS
====================
To/TO
investigate/VB
the/DT
clinical/JJ
validity/NN
of/IN
dPCR/NN
for/IN
kidney/NN
transplantation/NN
monitoring/VBG
,/,
we/PRP
screened/VBD
a/DT
total/JJ
of/IN
34/CD
kidney/NN
transplant/JJ
patients/NNS
'/``
urine/NN
cfDNA/JJ
samples/NNS
collected/JJ
at/IN
multiple/JJ
time/NN
points/NNS
after/IN
transplantation/NN
./.
====================
Among/IN
the/DT
34/CD
patients/NNS
,/,
we/PRP
selected/VBD
11/CD
patients/NNS
based/VBN
on/IN
TaqMan/NN
probe/NN
(/(
Applied/VBN
Biosystems/NNS
,/,
Foster/NN
City/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
availability/NN
to/TO
detect/VB
SNPs/NNS
for/IN
donor-specific/JJ
DNA/NN
(/(
plasma/NN
samples/NNS
n/NN
=/JJ
28/CD
,/,
urine/NN
samples/NNS
n/NN
=/JJ
25/CD
)/)
./.
====================
We/PRP
measured/VBD
the/DT
total/JJ
positive/JJ
DNA/NN
counts/NNS
,/,
and/CC
the/DT
percentage/NN
of/IN
the/DT
total/JJ
positive/JJ
DNA/NN
counts/NNS
that/DT
were/VBD
from/IN
donor/NN
DNA/NN
(/(
Fig/NN
./.
====================
4/CD
)/)
./.
====================
In/IN
a/DT
pilot/NN
test/NN
,/,
limited/JJ
amounts/NNS
of/IN
donor-specific/JJ
DNA/NN
were/VBD
detected/VBN
in/IN
plasma/NN
cfDNA/NN
samples/NNS
(/(
mean/NN
,/,
1/CD
%/NN
;/:
range/NN
,/,
0/CD
%/NN
to/TO
10/CD
%/NN
)/)
./.
====================
Conversely/RB
,/,
in/IN
urine/NN
cfDNA/JJ
samples/NNS
,/,
a/DT
large/JJ
percentage/NN
of/IN
the/DT
total/JJ
positive/JJ
DNA/NN
counts/NNS
were/VBD
from/IN
donor/NN
DNA/NN
(/(
mean/NN
,/,
55/CD
%/NN
;/:
range/NN
,/,
6/CD
%/NN
to/TO
100/CD
%/NN
)/)
./.
====================
However/RB
,/,
the/DT
differences/NNS
in/IN
both/DT
total/JJ
positive/JJ
DNA/NN
counts/NNS
,/,
and/CC
donor/NN
DNA/NN
percentages/NNS
,/,
were/VBD
not/RB
significant/JJ
between/IN
clinical/JJ
groups/NNS
(/(
Fig/NN
./.
====================
4/CD
)/)
./.
====================
We/PRP
next/RB
tested/VBN
whether/IN
circulating/VBG
mtDNA/JJ
could/MD
be/VB
used/VBN
to/TO
monitor/VB
graft/NN
status/NN
in/IN
transplant/JJ
patients/NNS
./.
====================
We/PRP
measured/VBD
the/DT
circulating/VBG
mtDNA/JJ
levels/NNS
in/IN
plasma/NN
and/CC
urine/NN
cfDNA/JJ
samples/NNS
from/IN
kidney/NN
transplant/JJ
patients/NNS
,/,
using/VBG
the/DT
mitochondrial/JJ
variant/JJ
marker/NN
mtDNA_12705/NN
./.
====================
We/PRP
found/VBD
that/IN
the/DT
circulating/VBG
mtDNA/JJ
levels/NNS
of/IN
transplant/JJ
patients/NNS
likewise/VBP
could/MD
not/RB
be/VB
used/VBN
to/TO
distinguish/VB
the/DT
clinical/JJ
conditions/NNS
of/IN
the/DT
patients/NNS
(/(
data/NNS
not/RB
shown/VBN
)/)
./.
====================
The/DT
donor-specific/JJ
cfDNA/JJ
in/IN
urine/NN
samples/NNS
was/VBD
not/RB
consistent/JJ
with/IN
the/DT
graft/NN
pathology/NN
,/,
or/CC
the/DT
results/NNS
of/IN
serum/NN
creatinine/VBP
analysis/NN
(/(
Fig/NN
./.
====================
5/CD
)/)
./.
====================
Plasma/NN
donor-specific/JJ
DNA/NN
was/VBD
not/RB
detected/VBN
in/IN
most/JJS
cases/NNS
,/,
but/CC
when/WRB
detected/VBN
it/PRP
was/VBD
also/RB
inconsistent/JJ
with/IN
graft/NN
function/NN
and/CC
patient/NN
status/NN
./.
====================
These/DT
results/NNS
indicate/VBP
that/IN
SNP-based/JJ
dPCR/NN
detection/NN
of/IN
donor/NN
DNA/NN
is/VBZ
not/RB
a/DT
useful/JJ
diagnostic/JJ
for/IN
determining/VBG
the/DT
clinical/JJ
conditions/NNS
of/IN
kidney/NN
transplant/JJ
patients/NNS
./.
====================
Acute/JJ
and/CC
chronic/JJ
rejection/NN
play/VBP
critical/JJ
roles/NNS
in/IN
graft/NN
function/NN
,/,
and/CC
patient/NN
survival/NN
,/,
following/VBG
kidney/NN
transplantation/NN
[/(
17/CD
]/)
./.
====================
Therefore/RB
,/,
monitoring/VBG
for/IN
kidney/NN
rejection/NN
is/VBZ
very/RB
important/JJ
./.
====================
The/DT
standard/JJ
for/IN
monitoring/VBG
kidney/NN
transplant/JJ
patients/NNS
is/VBZ
to/TO
regularly/RB
check/NN
serum/NN
creatinine/VBP
levels/NNS
[/(
2/CD
]/)
./.
====================
Assessment/JJ
of/IN
graft/NN
function/NN
can/MD
be/VB
supplemented/VBN
with/IN
a/DT
surveillance/NN
graft/NN
biopsy/NN
,/,
but/CC
the/DT
role/NN
of/IN
this/DT
invasive/JJ
procedure/NN
in/IN
monitoring/VBG
stable/JJ
,/,
un-sensitized/VBD
patients/NNS
is/VBZ
debatable/JJ
./.
====================
These/DT
methods/NNS
have/VBP
drawbacks/VBZ
including/VBG
low/JJ
specificity/NN
and/CC
injury/NN
,/,
respectively/RB
./.
====================
Many/JJ
researchers/NNS
have/VBP
tried/VBN
to/TO
develop/VB
alternative/JJ
or/CC
supplementary/JJ
methods/NNS
for/IN
monitoring/VBG
transplant/JJ
recipients/NNS
./.
====================
One/CD
of/IN
the/DT
promising/JJ
methods/NNS
of/IN
monitoring/VBG
for/IN
graft/NN
rejection/NN
is/VBZ
dPCR/NN
[/(
91012/CD
]/)
./.
====================
However/RB
,/,
it/PRP
is/VBZ
still/RB
not/RB
clear/JJ
whether/IN
dPCR/NN
is/VBZ
accurate/JJ
enough/IN
to/TO
use/VB
for/IN
the/DT
monitoring/JJ
of/IN
the/DT
clinical/JJ
conditions/NNS
of/IN
transplant/JJ
patients/NNS
./.
====================
Thus/RB
,/,
in/IN
this/DT
study/NN
,/,
we/PRP
evaluated/VBD
noninvasive/JJ
dPCR/NN
based/VBN
measurement/NN
of/IN
donor/NN
DNA/NN
levels/NNS
in/IN
patient/NN
plasma/NN
and/CC
urine/NN
as/IN
a/DT
technique/NN
for/IN
determining/VBG
the/DT
clinical/JJ
conditions/NNS
of/IN
kidney/NN
transplant/JJ
patients/NNS
./.
====================
dPCR/NN
is/VBZ
a/DT
sensitive/JJ
and/CC
cost-effective/JJ
method/NN
to/TO
quantify/VB
circulating/VBG
nucleic/JJ
acids/NNS
in/IN
samples/NNS
with/IN
a/DT
high/JJ
background/NN
of/IN
homologous/JJ
sequences/NNS
[/(
18/CD
]/)
./.
====================
We/PRP
initially/RB
compared/VBN
three/CD
dPCR/NN
instruments/NNS
(/(
QX200/CD
,/,
RainDrop/NN
,/,
and/CC
QuantStudio/NN
3D/NN
)/)
using/VBG
control/JJ
genomic/JJ
DNA/NN
samples/NNS
with/IN
known/VBN
genotypes/NNS
./.
====================
The/DT
Bio-Rad/JJ
QX200/CD
dPCR/NN
system/NN
had/VBD
the/DT
best/JJS
performance/NN
coupled/VBN
with/IN
accurate/JJ
DNA/NN
quantification/NN
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
The/DT
Bio-Rad/JJ
QX200/CD
droplet/NN
digital/JJ
PCR/NN
uses/VBZ
emulsion/NN
chemistry/NN
to/TO
partition/NN
20/CD
µL/NN
nucleic/JJ
acid/NN
samples/NNS
into/IN
approximately/RB
20,000/CD
oil-encapsulated/VBN
nanodroplets/NNS
to/TO
produce/VB
data/NNS
with/IN
high/JJ
sensitivity/NN
[/(
19/CD
]/)
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
the/DT
RainDrop/NN
and/CC
QuantStudio/NN
3D/NN
dPCR/NN
systems/NNS
had/VBD
high/JJ
false/VBP
positive/JJ
rates/NNS
and/CC
inaccurate/JJ
genotype/NN
clustering/NN
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
The/DT
QX200/CD
dPCR/NN
system/NN
robustly/RB
detected/VBN
high/JJ
copy/NN
numbers/NNS
of/IN
donor-specific/JJ
cfDNA/JJ
within/IN
kidney/NN
transplant/JJ
patient/NN
urine/NN
cfDNA/JJ
samples/NNS
,/,
but/CC
not/RB
plasma/NN
cfDNA/NN
samples/NNS
./.
====================
These/DT
results/NNS
indicate/VBP
that/IN
urine/NN
is/VBZ
a/DT
reliable/JJ
source/NN
of/IN
cfDNA/JJ
that/DT
can/MD
be/VB
analyzed/VBN
by/IN
dPCR/NN
to/TO
determine/VB
the/DT
levels/NNS
of/IN
donor-specific/JJ
cfDNA/JJ
following/VBG
kidney/NN
transplantation/NN
./.
====================
The/DT
weak/JJ
detection/NN
of/IN
donor-derived/JJ
cfDNA/JJ
in/IN
plasma/NN
samples/NNS
was/VBD
likely/JJ
due/JJ
to/TO
the/DT
high/JJ
background/NN
of/IN
recipient/JJ
DNA/NN
from/IN
hematopoietic/JJ
cells/NNS
[/(
1620/CD
]/)
./.
====================
Next-generation/NN
sequencing/NN
methods/NNS
can/MD
be/VB
used/VBN
with/IN
plasma/NN
DNA/NN
samples/NNS
for/IN
transplant/JJ
monitoring/VBG
with/IN
good/JJ
performance/NN
[/(
8/CD
]/)
because/IN
next-generation/NN
sequencing/NN
has/VBZ
better/RBR
detection/NN
power/JJR
than/IN
dPCR/NN
[/(
21/CD
]/)
./.
====================
However/RB
,/,
next-generation/NN
sequencing/NN
is/VBZ
difficult/JJ
and/CC
expensive/JJ
to/TO
use/VB
in/IN
a/DT
clinical/JJ
setting/VBG
./.
====================
Preamplification/NN
of/IN
cfDNA/JJ
by/IN
PCR/NN
is/VBZ
another/DT
option/NN
to/TO
enrich/JJ
the/DT
cfDNA/JJ
isolated/VBN
from/IN
plasma/NN
prior/JJ
to/TO
dPCR/NN
screening/NN
,/,
and/CC
this/DT
approach/NN
has/VBZ
been/VBN
used/VBN
in/IN
a/DT
previous/JJ
study/NN
[/(
10/CD
]/)
./.
====================
Highly/RB
polymorphic/JJ
SNPs/NNS
can/MD
be/VB
used/VBN
to/TO
detect/VB
donor-specific/JJ
DNA/NN
in/IN
transplant/JJ
recipients/NNS
./.
====================
Some/DT
researchers/NNS
have/VBP
used/VBN
Y-chromosome/NN
markers/NNS
to/TO
identify/VB
and/CC
measure/VB
donor/NN
DNA/NN
in/IN
gender-mismatched/VBN
transplantations/NNS
[/(
92122/CD
]/)
./.
====================
Also/RB
,/,
many/JJ
studies/NNS
have/VBP
used/VBN
SNPs/NNS
to/TO
determine/VB
the/DT
percentage/NN
of/IN
donor-derived/JJ
cfDNA/JJ
with/IN
dPCR/NN
[/(
10/CD
]/)
or/CC
next-generation/JJ
sequencing/NN
[/(
8/CD
]/)
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
used/VBD
highly/RB
polymorphic/JJ
nuclear/JJ
SNPs/NNS
that/DT
had/VBD
been/VBN
used/VBN
for/IN
identifying/VBG
individuals/NNS
[/(
13/CD
]/)
to/TO
detect/VB
and/CC
measure/VB
donor/NN
DNA/NN
./.
====================
We/PRP
evaluated/VBD
multiple/JJ
SNPs/NNS
,/,
including/VBG
autosomal/JJ
,/,
sex-specific/JJ
,/,
and/CC
mitochondrial/JJ
SNPs/NNS
./.
====================
Highly/RB
polymorphic/JJ
autosomal/JJ
SNPs/NNS
were/VBD
excellent/JJ
for/IN
identifying/VBG
donor-specific/JJ
DNA/NN
variants/NNS
./.
====================
As/IN
shown/VBN
in/IN
Table/JJ
1/CD
,/,
as/IN
few/JJ
as/IN
24/CD
%/NN
of/IN
the/DT
autosomal/JJ
SNPs/NNS
used/VBN
for/IN
human/JJ
identification/NN
are/VBP
needed/VBN
for/IN
donor/NN
DNA/NN
identification/NN
,/,
even/RB
in/IN
transplants/NNS
between/IN
related/JJ
individuals/NNS
./.
====================
In/IN
addition/NN
,/,
we/PRP
confirmed/VBD
that/IN
mtDNA/JJ
markers/NNS
are/VBP
ideal/JJ
for/IN
donor-specific/JJ
DNA/NN
detection/NN
in/IN
circulating/VBG
cfDNA/JJ
,/,
although/IN
they/PRP
can/MD
not/RB
be/VB
used/VBN
when/WRB
transplants/NNS
occur/VBP
between/IN
family/NN
members/NNS
of/IN
the/DT
same/JJ
mitochondrial/JJ
lineage/NN
./.
====================
Another/DT
issue/NN
when/WRB
using/VBG
mtDNA/JJ
SNPs/NNS
as/IN
markers/NNS
in/IN
transplantation/NN
monitoring/VBG
is/VBZ
the/DT
limited/JJ
availability/NN
of/IN
highly/RB
polymorphic/JJ
mitochondrial/JJ
SNPs/NNS
,/,
and/CC
the/DT
high/JJ
linkage/NN
between/IN
these/DT
SNPs/NNS
(/(
Table/JJ
2/CD
)/)
./.
====================
Furthermore/RB
,/,
as/IN
shown/VBN
in/IN
Fig/NN
./.
====================
2/CD
,/,
the/DT
percentage/NN
of/IN
mtDNA/JJ
that/DT
was/VBD
donor-derived/VBN
in/IN
urine/NN
did/VBD
not/RB
match/VB
the/DT
percentage/NN
of/IN
nuclear/JJ
DNA/NN
that/IN
was/VBD
donor-derived/VBN
./.
====================
It/PRP
has/VBZ
been/VBN
reported/VBN
that/IN
mtDNA/JJ
concentration/NN
is/VBZ
highly/RB
affected/VBN
by/IN
the/DT
blood-processing/VBG
protocol/NN
[/(
23/CD
]/)
,/,
and/CC
no/DT
correlation/NN
was/VBD
also/RB
observed/VBN
between/IN
the/DT
levels/NNS
of/IN
circulating/VBG
mtDNA/JJ
and/CC
genomic/JJ
DNA/NN
in/IN
previous/JJ
studies/NNS
[/(
2425/CD
]/)
./.
====================
Therefore/RB
,/,
mtDNA/JJ
markers/NNS
may/MD
not/RB
be/VB
better/RBR
than/IN
autosomal/JJ
SNPs/NNS
for/IN
transplantation/NN
monitoring/VBG
because/IN
the/DT
donor-derived/JJ
mtDNA/JJ
levels/NNS
in/IN
plasma/NN
and/CC
urine/NN
may/MD
vary/VB
widely/RB
between/IN
transplant/JJ
patients/NNS
,/,
depending/VBG
on/IN
the/DT
cell/NN
types/NNS
involved/VBN
in/IN
different/JJ
pathological/JJ
conditions/NNS
./.
====================
We/PRP
also/RB
found/VBD
that/IN
sex-specific/JJ
SNPs/NNS
were/VBD
as/IN
useful/JJ
as/IN
autosomal/JJ
SNPs/NNS
to/TO
monitor/VB
transplanted/VBN
organ/NN
status/NN
in/IN
cases/NNS
of/IN
gender-mismatched/VBN
transplantation/NN
,/,
particularly/RB
when/WRB
the/DT
donors/NNS
are/VBP
male/JJ
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
In/IN
kidney/NN
transplantation/NN
patients/NNS
,/,
very/RB
limited/JJ
numbers/NNS
of/IN
donor/NN
DNA/NN
were/VBD
detected/VBN
in/IN
plasma/NN
,/,
whereas/IN
sufficient/JJ
numbers/NNS
of/IN
donor/NN
DNA/NN
were/VBD
detected/VBN
in/IN
urine/NN
samples/NNS
./.
====================
Therefore/RB
,/,
for/IN
the/DT
detection/NN
of/IN
donor/NN
DNA/NN
in/IN
kidney/NN
transplantation/NN
,/,
we/PRP
think/VBP
that/DT
minimum/JJ
number/NN
of/IN
DNA/NN
copies/NNS
is/VBZ
10/CD
copies/NNS
and/CC
100/CD
copies/NNS
for/IN
plasma/NN
and/CC
urine/NN
samples/NNS
,/,
respectively/RB
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
found/VBD
that/IN
urine/NN
was/VBD
a/DT
much/RB
better/RBR
source/NN
of/IN
cfDNA/JJ
than/IN
plasma/NN
,/,
because/IN
it/PRP
contained/VBD
higher/JJR
copy/NN
numbers/NNS
of/IN
DNA/NN
./.
====================
This/DT
observation/NN
is/VBZ
consistent/JJ
with/IN
previously/RB
published/VBN
findings/NNS
[/(
92226/CD
]/)
./.
====================
Plasma/NN
donor-derived/VBN
cfDNA/NN
levels/NNS
might/MD
also/RB
be/VB
correlated/VBN
with/IN
the/DT
size/NN
of/IN
grafted/JJ
organ/NN
./.
====================
Even/RB
when/WRB
stable/JJ
,/,
liver/NN
transplant/JJ
patients/NNS
showed/VBD
higher/JJR
levels/NNS
of/IN
donor-derived/JJ
cfDNA/JJ
than/IN
kidney/NN
or/CC
heart/NN
transplantation/NN
patients/NNS
[/(
10/CD
]/)
./.
====================
Because/IN
of/IN
the/DT
limited/JJ
amount/NN
of/IN
donor-specific/JJ
cfDNA/JJ
in/IN
blood/NN
,/,
a/DT
plasma/NN
sample/NN
might/MD
not/RB
be/VB
suitable/JJ
for/IN
detecting/VBG
subtle/JJ
injuries/NNS
to/TO
the/DT
grafted/JJ
kidney/NN
./.
====================
In/IN
contrast/NN
,/,
urine/NN
contains/VBZ
sufficient/JJ
amounts/NNS
of/IN
donor-specific/JJ
cfDNA/NN
,/,
even/RB
in/IN
patients/NNS
with/IN
no/DT
abnormal/JJ
pathology/NN
./.
====================
Perhaps/RB
not/RB
surprisingly/RB
,/,
given/VBN
the/DT
massive/JJ
tubular/JJ
network/NN
,/,
2,000–7,000/CD
cells/NNS
are/VBP
detached/VBN
from/IN
this/DT
system/NN
daily/RB
and/CC
can/MD
be/VB
collected/VBN
in/IN
urine/NN
[/(
27/CD
]/)
./.
====================
Degradation/NN
of/IN
detached/VBN
tubular/JJ
cells/NNS
could/MD
be/VB
a/DT
source/NN
of/IN
urinary/JJ
cfDNA/NN
./.
====================
Our/PRP$
results/NNS
show/VBP
that/IN
the/DT
mean/JJ
percentage/NN
of/IN
cfDNA/JJ
that/DT
was/VBD
donor-specific/JJ
cfDNA/JJ
was/VBD
53.3/CD
%/NN
(/(
range/NN
,/,
21/CD
%/NN
to/TO
92/CD
%/NN
)/)
in/IN
patients/NNS
with/IN
stable/JJ
graft/NN
function/NN
and/CC
no/DT
pathological/JJ
abnormalities/NNS
./.
====================
We/PRP
can/MD
assume/VB
that/DT
half/NN
of/IN
the/DT
urinary/JJ
cfDNA/NN
originated/VBN
from/IN
the/DT
kidney/NN
,/,
whereas/IN
the/DT
other/JJ
half/NN
might/MD
be/VB
derived/VBN
from/IN
the/DT
urinary/JJ
tract/NN
./.
====================
Our/PRP$
hypothesis/NN
was/VBD
that/DT
a/DT
damaged/JJ
or/CC
rejected/JJ
graft/NN
would/MD
have/VBP
shown/VBN
increased/VBD
excretion/NN
of/IN
donor-specific/JJ
cfDNA/JJ
,/,
and/CC
this/DT
would/MD
be/VB
detected/VBN
in/IN
the/DT
urine/NN
./.
====================
However/RB
,/,
in/IN
clinical/JJ
sample/NN
screening/NN
,/,
although/IN
dPCR/NN
accurately/RB
detected/VBN
donor-specific/JJ
DNA/NN
in/IN
urine/NN
cfDNA/JJ
samples/NNS
,/,
we/PRP
could/MD
not/RB
find/VB
any/DT
statistically/RB
significant/JJ
difference/NN
between/IN
patients/NNS
with/IN
different/JJ
clinical/JJ
conditions/NNS
./.
====================
The/DT
amount/NN
of/IN
urinary/JJ
cfDNA/NN
was/VBD
highly/RB
variable/JJ
,/,
even/RB
in/IN
stable/JJ
patients/NNS
,/,
and/CC
was/VBD
not/RB
correlated/VBN
with/IN
graft/NN
pathology/NN
or/CC
function/NN
./.
====================
We/PRP
think/VBP
that/DT
multiple/JJ
factors/NNS
,/,
such/JJ
as/IN
patient/NN
age/NN
,/,
body/NN
weight/NN
,/,
time/NN
after/IN
operation/NN
,/,
clinical/JJ
complications/NNS
,/,
and/CC
variability/NN
in/IN
sample/JJ
preparation/NN
could/MD
contribute/VB
to/TO
the/DT
high/JJ
inter-patient/JJ
differences/NNS
in/IN
cfDNA/JJ
levels/NNS
./.
====================
Consistent/JJ
with/IN
our/PRP$
results/NNS
,/,
high/JJ
inter-patient/JJ
variation/NN
in/IN
cfDNA/JJ
has/VBZ
been/VBN
also/RB
demonstrated/VBD
in/IN
a/DT
previous/JJ
kidney/NN
transplantation/NN
study/NN
[/(
9/CD
]/)
./.
====================
In/IN
conclusion/NN
,/,
noninvasive/JJ
monitoring/VBG
of/IN
the/DT
levels/NNS
of/IN
donor-specific/JJ
cfDNA/JJ
is/VBZ
possible/JJ
,/,
and/CC
is/VBZ
a/DT
promising/JJ
approach/NN
to/TO
tracking/VBG
graft/NN
status/NN
and/CC
detecting/VBG
clinical/JJ
conditions/NNS
such/JJ
as/IN
acute/JJ
rejection/NN
./.
====================
However/RB
,/,
due/JJ
to/TO
high/JJ
inter-patient/JJ
variation/NN
,/,
and/CC
the/DT
complexity/NN
of/IN
patient/NN
cfDNA/JJ
samples/NNS
,/,
accurate/VBP
prediction/NN
of/IN
a/DT
patient/NN
's/POS
clinical/JJ
condition/NN
is/VBZ
currently/RB
not/RB
possible/JJ
./.
====================
Therefore/RB
,/,
further/RB
optimization/NN
of/IN
donor-derived/JJ
cfDNA/JJ
measurement/NN
by/IN
dPCR/NN
is/VBZ
necessary/JJ
before/IN
this/DT
technique/NN
can/MD
be/VB
implemented/VBN
clinically/RB
for/IN
noninvasive/JJ
monitoring/VBG
of/IN
kidney/NN
transplant/JJ
recipients/NNS
./.
====================
Comparison/NN
of/IN
the/DT
sensitivity/NN
and/CC
accuracy/NN
of/IN
three/CD
different/JJ
digital/JJ
polymerase/NN
chain/NN
reaction/NN
systems/NNS
(/(
Bio-Rad/NNP
QX200/CD
,/,
RainDance/NN
RainDrop/NN
,/,
and/CC
Life/NN
Technologies/NNS
QuantStudio/NN
3D/NN
)/)
in/IN
single/JJ
nucleotide/NN
polymorphism/NN
rs543840/CD
(/(
A/G/NN
)/)
detection/NN
in/IN
control/JJ
genomic/JJ
DNA/NN
samples/NNS
./.
====================
The/DT
numbers/NNS
of/IN
positive/JJ
counts/NNS
for/IN
each/DT
allele/NN
are/VBP
shown/VBN
in/IN
the/DT
genotyping/VBG
image/NN
plots/NNS
./.
====================
Detection/NN
of/IN
a/DT
single/JJ
nucleotide/NN
polymorphism/NN
(/(
SNP/NN
)/)
used/VBN
for/IN
determining/VBG
sex/NN
(/(
AMEL-1/NN
)/)
,/,
an/DT
autosomal/JJ
SNP/NN
for/IN
human/JJ
identification/NN
(/(
rs28-28793/CD
)/)
,/,
and/CC
a/DT
mitochondrial/JJ
DNA/NN
(/(
mtDNA/JJ
)/)
SNP/NN
(/(
mtDNA_3010/CD
)/)
using/VBG
digital/JJ
polymerase/NN
chain/NN
reaction/NN
in/IN
plasma/NN
and/CC
urine/NN
cell-free/JJ
deoxyribonucleic/JJ
acid/NN
samples/NNS
./.
====================
Samples/NNS
were/VBD
isolated/VBN
from/IN
a/DT
patient/NN
with/IN
acute/JJ
tubular/JJ
necrosis/NN
18/CD
days/NNS
after/IN
receiving/VBG
a/DT
kidney/NN
transplant/JJ
./.
====================
In/IN
this/DT
patient/NN
(/(
patient/NN
24/CD
)/)
,/,
an/DT
unrelated/JJ
male/JJ
donor/NN
's/POS
organ/NN
was/VBD
transplanted/VBN
into/IN
a/DT
female/JJ
recipient/JJ
./.
====================
Comparison/NN
of/IN
three/CD
different/JJ
types/NNS
of/IN
single/JJ
nucleotide/NN
polymorphisms/NNS
(/(
SNPs/NNS
)/)
(/(
autosomal/JJ
,/,
mitochondrial/JJ
,/,
or/CC
sex-specific/JJ
)/)
as/IN
markers/NNS
for/IN
quantification/NN
of/IN
donor/NN
DNA/NN
in/IN
kidney/NN
transplant/JJ
recipients/NNS
'/``
urine/NN
./.
====================
The/DT
correlation/NN
coefficient/JJ
(/(
r/NN
)/)
was/VBD
calculated/VBN
for/IN
pairwise/JJ
comparisons/NNS
of/IN
the/DT
donor/NN
DNA/NN
percentages/NNS
estimated/VBN
using/VBG
the/DT
three/CD
markers/NNS
,/,
with/IN
the/DT
autosomal/JJ
versus/CC
the/DT
sex-specific/JJ
SNP/NN
shown/VBN
(/(
A/DT
)/)
,/,
the/DT
autosomal/JJ
versus/CC
the/DT
mitochondrial/JJ
SNP/NN
shown/VBN
(/(
B/NN
)/)
,/,
and/CC
the/DT
sex-specific/JJ
versus/CC
the/DT
mitochondrial/JJ
SNP/NN
shown/VBN
(/(
C/NN
)/)
./.
====================
Detection/NN
of/IN
total/JJ
positive/JJ
DNA/NN
counts/NNS
(/(
A/DT
)/)
and/CC
donor/NN
DNA/NN
%/NN
(/(
B/NN
)/)
in/IN
urine/NN
cell-free/JJ
deoxyribonucleic/JJ
acid/NN
samples/NNS
using/VBG
digital/JJ
polymerase/NN
chain/NN
reaction/NN
(/(
dPCR/NN
)/)
based/VBN
single/JJ
nucleotide/NN
polymorphism/NN
(/(
SNP/NN
)/)
-identification/JJ
./.
====================
Patients/NNS
are/VBP
grouped/VBN
based/VBN
on/IN
clinical/JJ
condition/NN
as/IN
indicated/VBD
along/IN
the/DT
x-axis/NN
./.
====================
The/DT
“/NN
Others/NNS
”/CD
group/NN
includes/VBZ
two/CD
injured/JJ
patients/NNS
(/(
▼/CD
)/)
,/,
one/CD
patient/NN
with/IN
calcineurin/NN
inhibitor/NN
toxicity/NN
(/(
▲/CD
)/)
and/CC
one/CD
patient/NN
with/IN
glomerulonephritis/NN
(/(
◆/CD
)/)
./.
====================
The/DT
donor/NN
DNA/NN
counts/NNS
were/VBD
detected/VBN
by/IN
SNP-based/JJ
dPCR/NN
using/VBG
an/DT
autosomal/JJ
SNP/NN
or/CC
a/DT
sex-specific/JJ
SNP/NN
as/IN
described/VBN
in/IN
the/DT
Methods/NNS
./.
====================
Mean/JJ
values/NNS
are/VBP
indicated/VBN
with/IN
horizontal/JJ
bar/JJ
in/IN
each/DT
group/NN
./.
====================
No/DT
significance/NN
of/IN
the/DT
difference/NN
between/IN
the/DT
mean/JJ
total/JJ
positive/JJ
DNA/NN
counts/NNS
for/IN
the/DT
stable/JJ
group/NN
and/CC
acute/JJ
rejection/NN
group/NN
was/VBD
observed/VBN
by/IN
a/DT
student/JJ
's/POS
t/NN
test/NN
(/(
A/DT
)/)
./.
====================
Change/NN
in/IN
donor/NN
DNA/NN
percentage/NN
over/IN
time/NN
after/IN
transplantation/NN
is/VBZ
presented/VBN
for/IN
three/CD
representative/JJ
patients/NNS
./.
====================
Urine/NN
(/(
left/NN
)/)
and/CC
plasma/NN
(/(
right/JJ
)/)
donor-specific/JJ
cell-free/JJ
deoxyribonucleic/JJ
acid/NN
(/(
cfDNA/JJ
)/)
were/VBD
expressed/VBN
as/IN
percentage/NN
of/IN
the/DT
total/JJ
cfDNA/NN
./.
====================
The/DT
legends/NNS
show/VBP
details/VBZ
about/RB
the/DT
conditions/NNS
of/IN
the/DT
patient/NN
,/,
such/JJ
as/IN
acute/JJ
tubular/JJ
necrosis/NN
(/(
ATN/NN
)/)
,/,
acute/JJ
cellular/JJ
rejection/NN
(/(
ACR/NN
)/)
,/,
antibody-mediated/JJ
rejection/NN
(/(
AMR/NN
)/)
,/,
or/CC
borderline/JJ
./.
====================
The/DT
grades/NNS
of/IN
rejection/NN
(/(
IA/NN
,/,
IIA/NN
)/)
and/CC
creatinine/VBP
levels/NNS
(/(
Cr/NN
)/)
were/VBD
also/RB
presented/VBN
in/IN
the/DT
Figure/NN
./.
====================
Summary/JJ
of/IN
data/NNS
from/IN
genotyping/VBG
three/CD
transplant/JJ
patients/NNS
,/,
with/IN
donor-recipient/JJ
paired/JJ
DNA/NN
samples/NNS
,/,
using/VBG
two/CD
sex-specific/JJ
SNPs/NNS
and/CC
27/CD
autosomal/JJ
SNPs/NNS
====================
Selection/NN
of/IN
seven/CD
highly/RB
polymorphic/JJ
mitochondrial/JJ
SNPs/NNS
for/IN
human/JJ
identification/NN
====================
